Today Marseille Immunopôle is a great opportunity to challenge our discipline with novel perspectives.

“Our immunotherapy antibodies are positioned at the crossroads of two immunology fields with high potential: the g9d2 T cells and a novel superfamily of immunomodulators, butyrophilins”

Understanding its mechanisms of action and proposing new diagnostic and therapeutic solutions is the ambitious project that we set with my team.

Marseille Immunopôle (Marseille Immunology Center) has the potential to provide precious help to open new diagnostic and therapeutic pathways and to provide our patients with even more options. 

Cell- and tissue- based therapies and gene therapies hold great promise in the field of both immunotherapy and regenerative medicine.

Today, the Covid-19 pandemic serves as an eye-opener, once again demonstrating the strength of the Marseille Immunopôle collective

MI carries a strong voice for immunology research, freeing partners from their public or private sectors, breaking down disciplinary barriers and creating the essential conditions for acting together, quickly and sustainably

MI-mAbs allows researchers to validate the therapeutic potential of their discovery and permits industrials to focus their efforts on the most promising drug candidate

Veracyte (formerly HaliodDx) is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.

For many years our service at the Timone Hospital has collaborated with researchers including the " Natural Killer Cells and Innate Immunity" team of Eric VIVIER .

Marseille Immunopole should allow us now to accelerate the development of therapeutic antibodies, the new drugs that are changing the course of cancer treatment.

MI both accelerates research and development in immuno-oncology and offers cancer patients more options in terms of diagnostics and treatments, as well as more innovative clinical trials.

Diagnostic in immuno-oncology is an innovative field combining the latest discoveries in immunology and new imaging technologies, such as digital pathology.

The Pioneer Project is unique as a strong public/private partnership between academia, a medical cancer center, 3 biotechs and a major pharma